Source:http://linkedlifedata.com/resource/pubmed/id/15926761
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1 Suppl
|
| pubmed:dateCreated |
2005-6-1
|
| pubmed:abstractText |
We sought to develop a budget impact model that assesses the economic effect of adding tegaserod for the management of irritable bowel syndrome (IBS) with constipation to the formulary of a managed care organization (MCO). The model estimates the per patient economic impact and the per member, per month (PMPM) economic impact of patients 6 months before and 6 months after the initiation of tegaserod. Resource utilization data, taken from medical and pharmacy administrative claims data, were based on a retrospective, longitudinal study of 3365 patients administered tegaserod through a large, geographically diverse MCO. Costs were estimated for 2 patient subgroups, women with IBS and other gastrointestinal (GI) diagnoses. Sensitivity analyses were performed by varying several model input parameters. The base-case model resulted in an incremental PMPM budget impact associated with the use of tegaserod of 0.01 dollars. Total per patient budget impact (for all resources, including tegaserod) for a 6-month period was 274.34 dollars for women with IBS and 301.84 dollars for women with other GI diagnoses. Overall, 25.9% (29.0% for women with IBS group and 21.9% for women with other GI diagnoses group) of the cost of tegaserod was offset by decreases in resource utilization. Key drivers of post-tegaserod reductions in resource costs were hospital stays, outpatient office visits, emergency department visits, endoscopic procedures, and nonendoscopic procedures. Tegaserod therapy can decrease GI-related resource utilization, resulting in a significant cost-offset percentage. When the associated budget impact of adding tegaserod to its formulary is absorbed across an entire MCO population, the PMPM impact of tegaserod is small.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
H
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1088-0224
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S27-34
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:15926761-Adult,
pubmed-meshheading:15926761-Budgets,
pubmed-meshheading:15926761-Constipation,
pubmed-meshheading:15926761-Cost of Illness,
pubmed-meshheading:15926761-Drug Costs,
pubmed-meshheading:15926761-Drug Prescriptions,
pubmed-meshheading:15926761-Female,
pubmed-meshheading:15926761-Formularies as Topic,
pubmed-meshheading:15926761-Gastrointestinal Agents,
pubmed-meshheading:15926761-Health Care Costs,
pubmed-meshheading:15926761-Humans,
pubmed-meshheading:15926761-Indoles,
pubmed-meshheading:15926761-Irritable Bowel Syndrome,
pubmed-meshheading:15926761-Longitudinal Studies,
pubmed-meshheading:15926761-Managed Care Programs,
pubmed-meshheading:15926761-Middle Aged,
pubmed-meshheading:15926761-Models, Statistical,
pubmed-meshheading:15926761-Retrospective Studies,
pubmed-meshheading:15926761-Serotonin Receptor Agonists,
pubmed-meshheading:15926761-United States,
pubmed-meshheading:15926761-Utilization Review
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Budget impact of tegaserod on a managed care organization formulary.
|
| pubmed:affiliation |
Innovative Health Solutions, Brookline, Massachusetts, USA.
|
| pubmed:publicationType |
Journal Article
|